Literature DB >> 20888666

Enhanced expression of soluble recombinant tetanus neurotoxin Hc in Escherichia coli as a tetanus vaccine candidate.

Rui Yu1, Lihua Hou, Changming Yu, Shuling Liu, Jun Ren, Ting Fang, Xiaoyan Zhang, Wei Chen.   

Abstract

The expression of the carboxyl fragment of the heavy chain of tetanus neurotoxin (TeNT-Hc) in Escherichia coli has been hampered by the unusually high AT content and the presence of rarely used codons by Clostridium. The gene encoding TeNT-Hc was optimized for E. coli by replacing rare codons and decreasing the AT pairs from 72.57% to 52.47%. The reconstructed gene was expressed in E. coli BL21(DE3) and resulted in a soluble product which was about 46% of the total bacterial protein. TeNT-Hc produced in a 42 L fermentor was purified to >95% at 87 g/kg of cell paste (approximately 333 mg/L). BALB/c mice vaccinated with three bi-weekly doses of TeNT-Hc with Freund's adjuvant were fully protected against an intraperitoneally challenge of 2 × 10(3) 50% lethal doses (LD(50)s) of tetanus neurotoxin. NIH mice vaccinated with TeNT-Hc adsorbed to aluminum hydroxide gel adjuvant demonstrated a potency of 168 IU/mL, which was 2 times higher than the national standard for tetanus vaccines. These results suggest that TeNT-Hc may be a promising second-generation vaccine candidate for clinical use against tetanus neurotoxin.
Copyright © 2010 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20888666     DOI: 10.1016/j.imbio.2010.09.001

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  11 in total

1.  A conformational change of C fragment of tetanus neurotoxin reduces its ganglioside-binding activity but does not destroy its immunogenicity.

Authors:  Rui Yu; Shaoqiong Yi; Changming Yu; Ting Fang; Shuling Liu; Ting Yu; Xiaohong Song; Ling Fu; Lihua Hou; Wei Chen
Journal:  Clin Vaccine Immunol       Date:  2011-08-03

2.  Utility of recombinant fragment C for assessment of anti-tetanus antibodies in plasma.

Authors:  Girija Ramakrishnan; Karl Pedersen; Denis Guenette; Joyce Sink; Rashidul Haque; William A Petri; Joel Herbein; Carol A Gilchrist
Journal:  Diagn Microbiol Infect Dis       Date:  2015-02-07       Impact factor: 2.803

3.  The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo.

Authors:  Alon Ben David; Eran Diamant; Ada Barnea; Osnat Rosen; Amram Torgeman; Ran Zichel
Journal:  Clin Vaccine Immunol       Date:  2013-06-12

4.  The Pneumococcal Polysaccharide-Tetanus Toxin Native C-Fragment Conjugate Vaccine: The Carrier Effect and Immunogenicity.

Authors:  Rui Yu; Junjie Xu; Tao Hu; Wei Chen
Journal:  Mediators Inflamm       Date:  2020-07-04       Impact factor: 4.711

Review 5.  Vaccine Production to Protect Animals Against Pathogenic Clostridia.

Authors:  Nicolas E Zaragoza; Camila A Orellana; Glenn A Moonen; George Moutafis; Esteban Marcellin
Journal:  Toxins (Basel)       Date:  2019-09-11       Impact factor: 4.546

Review 6.  Tetanus Toxin Fragment C: Structure, Drug Discovery Research and Production.

Authors:  Caroline Bayart; Angélique Mularoni; Nada Hemmani; Soumeya Kerachni; Joachim Jose; Patrice Gouet; Joseph Paladino; Marc Le Borgne
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-17

7.  Comparative Immunogenicity of the Tetanus Toxoid and Recombinant Tetanus Vaccines in Mice, Rats, and Cynomolgus Monkeys.

Authors:  Rui Yu; Ting Fang; Shuling Liu; Xiaohong Song; Changming Yu; Jianmin Li; Ling Fu; Lihua Hou; Junjie Xu; Wei Chen
Journal:  Toxins (Basel)       Date:  2016-06-25       Impact factor: 4.546

8.  Tetanus Neurotoxin Neutralizing Antibodies Screened from a Human Immune scFv Antibody Phage Display Library.

Authors:  Han Wang; Rui Yu; Ting Fang; Ting Yu; Xiangyang Chi; Xiaopeng Zhang; Shuling Liu; Ling Fu; Changming Yu; Wei Chen
Journal:  Toxins (Basel)       Date:  2016-09-11       Impact factor: 4.546

9.  The Immunogenicity of the C Fragment of Tetanus Neurotoxin in Production of Tetanus Antitoxin.

Authors:  Rui Yu; Chong Ji; Junjie Xu; Denghai Wang; Ting Fang; Yue Jing; Clifton Kwang-Fu Shen; Wei Chen
Journal:  Biomed Res Int       Date:  2018-12-31       Impact factor: 3.411

10.  Safety and Immunogenicity of a Recombinant Tetanus Vaccine in Healthy Adults in China: A Randomized, Double-Blind, Dose Escalation, Placebo- and Positive-Controlled, Phase 1/2 Trial.

Authors:  Xiaowei Xu; Rui Yu; Lanlan Xiao; Jie Wang; Meihong Yu; Junjie Xu; Yajun Tan; Xiao Ma; Xiaoxin Wu; Jiangshan Lian; Kaizhou Huang; Xiaoxi Ouyang; Sheng Bi; Shipo Wu; Xiaoyan Wang; Jiandi Jin; Ling Yu; Huafen Zhang; Qi Wei; Jinfa Shi; Wei Chen; Lanjuan Li
Journal:  Adv Sci (Weinh)       Date:  2021-06-03       Impact factor: 16.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.